Erin K. Brenner is Chief Product Dev. Officer at Pear Therapeutics, Inc. (PEAR). They have made 1 open-market trade across 1 company since 2023, most recently 2023-01-20.
CIK 0001881042
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PEAR | 43,310 | $1K |
Shares reported on the most recent Form 4, priced at the 2023-01-24 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PEAR | SELL | 2023-01-20 | 2023-01-24 | $1.13 | $10K | +5.5% | -5.5% | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.